Lukas Hainz

The precipitous downfall of a once-promising company often sends ripples through the investment community, signaling a dramatic shift in confidence and strategic outlook. Such is the case for EHealth, Inc. (EHTH), an online health insurance agency that has recently seen one of its institutional

The decade-long journey for a promising Duchenne muscular dystrophy treatment has reached a devastating conclusion, as PTC Therapeutics has officially withdrawn its application for Translarna from the U.S. market, marking the end of a contentious and ultimately unsuccessful bid for regulatory

The transition from the structured, high-stakes environment of military service to the ambiguities of civilian life often carries unseen burdens that extend far beyond the visible scars of conflict. For many veterans, the internal battles with hyper-vigilance, the persistent echo of trauma in

The United Kingdom's healthcare landscape has long presented a paradox for medical technology innovators, where groundbreaking devices and diagnostics capable of transforming patient outcomes often face a fragmented and unpredictable journey to widespread adoption within the National Health Service

The American biomedical research landscape has emerged into 2026 bearing the deep and complex scars of a profoundly turbulent year, navigating a delicate balance between a renewed sense of financial security and a pervasive anxiety over the integrity of its foundational institutions. Following a

The global map of Parkinson's disease is rapidly being redrawn, yet the landscape of the research dedicated to conquering it remains stubbornly fixed. A profound and widening disparity now exists between the populations most affected by this neurodegenerative condition and the focus of scientific

As an expert in robotics and IoT applications in medicine, James Maitland has dedicated his career to a powerful, singular passion: leveraging technology to advance healthcare solutions. Yet, he cautions that the industry's rush toward futuristic concepts like AI and virtual hospitals often

The landscape of serious illness care in the United States is fraught with challenges, leaving millions of vulnerable patients and their families navigating a fragmented and often reactive healthcare system. In this high-stakes environment, health technology company Vynca has made a definitive move

A contentious federal pilot program designed to overhaul how safety-net hospitals are compensated for prescription drugs has been abruptly withdrawn by the Department of Health and Human Services (HHS) following a decisive legal challenge. The proposed 340B Rebate Model Pilot, which was set to

After years of meteoric growth that redefined the landscape for innovative medical technology, the U.S. Food and Drug Administration's (FDA) Breakthrough Devices Program has settled into a new, more predictable rhythm. This shift from rapid acceleration to a consistent, high-volume cadence signals